Israël - anglais - Ministry of Health

kamada ltd, israel - conestat alfa - powder for solution for injection - conestat alfa 2100 u/vial - conestat alfa - ruconest is indicated for treatment of acute angioedema attacks in adults and adolescents aged 12 years and above with hereditary angioedema (hae) due to c1 esterase inhibitor deficiency.

Israël - anglais - Ministry of Health

kamada ltd, israel - rupatadine as fumarate - tablets - rupatadine as fumarate 10 mg - rupatadine - rupafin is indicated for symptomatic treatment of allergic rhinitis and urticaria in adults and adolescents (over 12 years of age)

Israël - anglais - Ministry of Health

kamada ltd, israel - human hepatitis b immunoglobulin - solution for infusion - human hepatitis b immunoglobulin 50 mg / 1 ml - immunoglobulins, normal human, for intravascular adm. - immunoglobulins, normal human, for intravascular adm. - prophylaxis against hepatitis b in adults and children over 2 years of age who have not been vaccinated against hepatitis b (including persons whose vaccination is incomplete or missing) who are at risk of infection with hepatitis b by accidental contact with hepatitis b virus containing material following: - percutaneous exposure (e.g. accidental needle stick). - direct mucous membrane contact. when the administration of an intramuscular hepatitis b immunoglobulin is not possible. the immunoglobulin should be administered in association with hepatitis b vaccine. prophylaxis against re-infection of a transplanted liver in patients who carry the surface antigen of the hepatitis b virus. immunoprophylaxis of hepatitis b in the newborn of a hepatitis b virus carrier mother.

Israël - anglais - Ministry of Health

kamada ltd, israel - immunoglobulins, normal human - solution for infusion - immunoglobulins, normal human 100 mg/ml - immunoglobulins, normal human, for intravascular adm. - replacement therapy in adults, and children and adolescents (0-18 years) in: - primary immunodeficiency syndromes (pid) with impaired antibody production - secondary immunodeficiencies (sid) in patients who suffer from severe or recurrent infections, ineffective antimicrobial treatment and either proven specific antibody failure (psaf)* or serum igg level of <4 g/l * psaf= failure to mount at least a 2-fold rise in igg antibody titre to pneumococcal polysaccharide and polypeptide antigen vaccinesimmunomodulation in adults, and children and adolescents (0-18 years) in: - primary immune thrombocytopenia (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count - guillain barré syndrome - kawasaki disease (in conjunction with acetylsalicylic acid) - chronic inflammatory demyelinating polyradiculoneuropathy (cidp) - multifocal motor neuropathy (mmn)

Israël - anglais - Ministry of Health

kamada ltd, israel - immunoglobulins, normal human - solution for infusion - immunoglobulins, normal human 5 g / 100 ml - immunoglobulins, normal human, for intravascular adm. - immunoglobulins, normal human, for intravascular adm. - replacement therapy in adults, and children and adolescents in:- primary immunodeficiency syndromes with impaired antibody production - hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic leukaemia, in whom prophylactic antibiotics have failed- hypogammaglobulinaemia and recurrent bacterial infections in plateau phase multiple myeloma patients who have failed to respond to pneumococcal immunisation- congenital aids with recurrent bacterial infectionsimmunomodulation in adults, and children and adolescents in:- primary immune thrombocytopenia (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count- guillain barré syndrome- kawasaki disease

Israël - anglais - Ministry of Health

kamada ltd, israel - albumin human - solution for infusion - albumin human 200 mg/ml - albumin - albumin - for restoration and maintenance of circulating blood volume where volume deficiency has been demontrated and use of a colloid such as albumin is appropriate. the choice of albumin rather than artificial colloid will depend on the clinical situation of the individual patient based on official recommendations.

Israël - anglais - Ministry of Health

kamada ltd, israel - japanese encephalitis purified inactivated vaccine - suspension for injection - japanese encephalitis purified inactivated vaccine 6 au / 0.5 ml - encephalitis, japanese, inactivated, whole virus - ixiaro is indicated for active immunization against japanese encephalitis in adults, adolescents, children and infants aged 2 months and older. ixiaro should be considered for use in individuals at risk of exposure through travel or in the course of their occupation.

Israël - anglais - Ministry of Health

kamada ltd, israel - viable salmonella typhi ty21a cells - gastro resistant hard capsule - viable salmonella typhi ty21a cells - vivotif is indicated for active oral immunisation against typhoid fever, caused by salmonella enterica serovar typhi, (s. typhi), in adults and children aged five years and older.this vaccine should be used in accordance with official recommendations

Israël - anglais - Ministry of Health

kamada ltd, israel - bevacizumab - concentrate for solution for infusion - bevacizumab 25 mg/ml - bevacizumab - - bevacizumab kamada in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of patients with metastatic carcinoma of the colon or rectum.- bevacizumab kamada in addition to platinum - based chemotherapy is indicated for first - line treatment of patients with unresectable advanced metastatic or recurrent non- small cell lung cancer other than predominantly squamous cell histology. - bevacizumab kamada in combination with interferon alfa-2a is indicated for first line treatment of patients with advanced and /or metastatic renal cell cancer.- bevacizumab kamada in combination with paclitaxel is indicated for first-line treatment of patients with metastatic breast cancer.- bevacizumab kamada as a single agent, is indicated for the treatment of glioblastoma in patients with progressive disease following prior therapy.- bevacizumab kamada in combination with carboplatin and paclitaxel, is indicated for the front-line treatment of advanced (figo stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who are at high risk for recurrence (residual disease after debulking).- bevacizumab kamada in combination with carboplatin and gemcitabine, is indicated for the treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor-targeted agents.- bevacizumab kamada in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents - bevacizumab kamada in combination with paclitaxel and cisplatin or paclitaxel and topotecan is indicated for treatment of patients with persistent, recurrent, or metastatic carcinoma of the cervix.- bevacizumab kamada in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations.

Israël - anglais - Ministry of Health

kamada ltd, israel - rupatadine as fumarate - solution - rupatadine as fumarate 1 mg / 1 ml - rupatadine - symptomatic treatment of:- allergic rhinitis (including persistent allergic rhinitis) in children aged 2 to 11 years - urticaria in children aged 2 to 11 years